Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Arcellx, Inc.

We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.


Kite Pharma

JVC Investment Partners

LG Technology Ventures

Solasta Ventures

Samsara BioCapital

Novo Holdings

Adage Capital Management

Asymmetry Ventures

CaaS Capital Management

Cambrian Biopharma

CAM Capital

Clough Capital Partners

Soleus Capital

SR One

Surveyor Capital

Suvretta Capital Management

Takeda Ventures

Terra Magnum Capital Partners (""""TMCP"""")""

Arcellx

NASDAQ:ACLX

Arcellx, Inc.

Last Close

84.44

25/09 14:39

Market Cap

3.07B

Beta: -

Volume Today

46.04K

Avg: 484.45K

PE Ratio

−24.88

PFCF: 30.94